Nodexus

Executive Summary

Nodexus is a San Francisco-based biotechnology company developing affordable, benchtop cell sorting and dispensing systems for the life sciences research market. Its flagship NX One platform leverages gentle microfluidic technology to enable single-cell analysis and sorting, with applications in genomics, diagnostics, and cell line development. Priced under $100,000, NX One aims to democratize access to high-precision cell sorting, traditionally dominated by bulky, expensive instruments. The company targets academic labs, biotech firms, and core facilities seeking cost-effective, benchtop solutions for single-cell workflows. With a founding year of 2018 and a focus on commercializing its platform, Nodexus is positioned to capture market share in the growing single-cell analysis space. The platform's gentle handling and integrated dispensing capabilities differentiate it from competitors by minimizing cell stress and enabling direct downstream processing. As research demands for single-cell resolution increase, Nodexus's value proposition of affordability and accessibility could drive adoption across a broad customer base. The company's success hinges on continued product refinement, customer traction, and strategic partnerships to scale its commercial footprint.

Upcoming Catalysts (preview)

• Q3 2026Series A or B funding announcement to scale manufacturing and sales60% success
• Q4 2026Key partnership with major genomics or diagnostics company for NX One integration40% success
• Q2 2026Publication of peer-reviewed study showcasing NX One performance in clinical or research application70% success